TD-JN898016

Obiltoxaximab(TD-IN898016) is a research-grade recombinant antibody targetingProtective antigen. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Bacillus anthracis

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Chimeric

IgG1-kappa

Monoclonal

Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P13423

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

ETI-204, 1351337-07-9

Obiltoxaximab (ETI-204, trade name Anthim) is an affinity-enhanced, chimeric IgG1 kappa monoclonal antibody (mAb) developed by Elusys Therapeutics and the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) for the prevention and treatment of inhalational anthrax due to Bacillus anthracis. Obiltoxaximab binds the protective antigen (PA) component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. Obiltoxaximab has been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment (in combination with appropriate antibacterial drugs) and prophylaxis of inhalational anthrax.

SEC-HPLC detection for Research Grade Obiltoxaximab.　　|　Detects PA/pagA/PA-83 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Obiltoxaximab　　|　Western blot analysis was performed using anti-PA/pagA/PA-83 monoclonal antibody at 1μg/ml on various samples.Lane 1:recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No:TD-JN898012), 50ngLane 2:recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No:TD-JN898012), 30ngLane 3:recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No:TD-JN898012), 20ngLane 4:recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No:TD-JN898012), 10ng

For research use only. Not suitable for clinical or therapeutic use.